Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Scott Obach

Showing results (61-70 of 193) with videos related to

Pageof 20
Sort By:
Journal of Medicinal Chemistry|June 14, 2002
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding dataFranco Lombardo, R Scott Obach, Marina Y Shalaeva, et al.
Journal of Clinical Pharmacology|December 19, 2003
Human liver aldehyde oxidase: inhibition by 239 drugsR Scott Obach, Phuong Huynh, Mary C Allen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 23, 2010
Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymesOdette A Fahmi, Mary Kish, Sherri Boldt, et al.
Journal of Medicinal Chemistry|February 20, 2004
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statisticsFranco Lombardo, R Scott Obach, Marina Y Shalaeva, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 18, 2005
Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigmKiyomi Ito, David Hallifax, R Scott Obach, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 10, 2016
Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro DataHoa Q Nguyen, Emi Kimoto, Ernesto Callegari, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 2, 2024
Evaluation of Icotinib as a Potent and Selective Inhibitor of Aldehyde Oxidase for Reaction Phenotyping in Human HepatocytesLloyd Wei Tat Tang, Ethan DaSilva, Kimberly Lapham, et al.
Journal of Medicinal Chemistry|January 6, 2025
Positioning Enzyme- and Transporter-Based Precipitant Drug-Drug Interaction Studies in Drug DesignThomas Schroeter, Kimberly Lapham, Manthena V S Varma, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 18, 2024
The Drug-Drug Interaction between Erlotinib and OSI-930 Is Mediated through Aldehyde Oxidase InhibitionLloyd Wei Tat Tang, Yuanyuan Shi, Raman Sharma, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|November 24, 2011
In vitro-in vivo correlation for intrinsic clearance for CP-409,092 and sumatriptan: a case study to predict the in vivo clearance for compounds metabolized by monoamine oxidaseAmin Kamel, Kevin Colizza, Mithat Gunduz, et al.
Pageof 20

Showing results (61-70 of 193) with videos related to

Sort By:
Pageof 20
Journal of Medicinal Chemistry|June 14, 2002
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding dataFranco Lombardo, R Scott Obach, Marina Y Shalaeva, et al.
Journal of Clinical Pharmacology|December 19, 2003
Human liver aldehyde oxidase: inhibition by 239 drugsR Scott Obach, Phuong Huynh, Mary C Allen, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 23, 2010
Cytochrome P450 3A4 mRNA is a more reliable marker than CYP3A4 activity for detecting pregnane X receptor-activated induction of drug-metabolizing enzymesOdette A Fahmi, Mary Kish, Sherri Boldt, et al.
Journal of Medicinal Chemistry|February 20, 2004
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statisticsFranco Lombardo, R Scott Obach, Marina Y Shalaeva, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 18, 2005
Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigmKiyomi Ito, David Hallifax, R Scott Obach, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 10, 2016
Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro DataHoa Q Nguyen, Emi Kimoto, Ernesto Callegari, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 2, 2024
Evaluation of Icotinib as a Potent and Selective Inhibitor of Aldehyde Oxidase for Reaction Phenotyping in Human HepatocytesLloyd Wei Tat Tang, Ethan DaSilva, Kimberly Lapham, et al.
Journal of Medicinal Chemistry|January 6, 2025
Positioning Enzyme- and Transporter-Based Precipitant Drug-Drug Interaction Studies in Drug DesignThomas Schroeter, Kimberly Lapham, Manthena V S Varma, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 18, 2024
The Drug-Drug Interaction between Erlotinib and OSI-930 Is Mediated through Aldehyde Oxidase InhibitionLloyd Wei Tat Tang, Yuanyuan Shi, Raman Sharma, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|November 24, 2011
In vitro-in vivo correlation for intrinsic clearance for CP-409,092 and sumatriptan: a case study to predict the in vivo clearance for compounds metabolized by monoamine oxidaseAmin Kamel, Kevin Colizza, Mithat Gunduz, et al.
Pageof 20